, suffered an 18% collapse. This divergence marks the end of the initial land-grab phase in obesity therapeutics and the beginning of a complex era defined by pricing power and market share erosion.
Why is Eli Lilly seeing surging sales as obesity rival Novo Nordisk plummets?
faces a multifaceted crisis. Their injectable market share has slipped to approximately 30-40%, a staggering decline for a first-mover in the space. This isn't a simple case of lower demand; it's a structural failure to defend territory against
is shifting toward oral therapies, which attract significant volume but command a mere fraction of the previous price point. Introductory rates of $150 per month represent a drastic haircut from the $300 to $500 seen in traditional injectable treatments. This transition effectively cannibalizes their high-margin business for high-volume, low-margin alternatives.
list. This inclusion mandates price negotiations and further degrades the company's long-term profitability outlook. Unlike its rivals, Novo is fighting a war on two fronts: market competition and government-mandated price compression. The result is a challenging near-term horizon that rewards the agility of
